According to the complaint, Amgen and its affiliates “have for many years infringed the Iowa Patents with full knowledge of them” to produce Enbrel (etanercept) and Vectibix (panitumumab).

Etanercept (Enbrel), approved in the United States and in Europe for use in patients with RA and JRA, is an effective inhibitor of TNF that has been shown to provide rapid and sustained improvement in ...

She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a subcutaneous injection into the left thigh, she developed a mildly pruritic eruption on the right thigh ...

The appeals court ruling blocks Sandoz from producing a biosimilar of Enbrel (etanercept) until 2029, more than thirty years after it was first approved. Sandoz, which is the biosimilars and ...

Amgen’s venerable TNF inhibitor Enbrel (etanercept) for arthritis and other inflammatory conditions topped the list of offenders in terms of the added cost to the healthcare system, which ICER ...

The Food and Drug Administration (FDA) has approved etanercept-szzs (brand name: Erelzi), a biosimilar form of etanercept (Enbrel), to treat rheumatoid arthritis (RA), psoriatic arthritis, ankylosing ...